Chronic Obstructive Pulmonary Disease (COPD) Market Global Forecast Report by Types (Chronic Bronchitis, Emphysema) Treatment Types (Drugs, Oxygen Therapy, Surgery, Others) Distribution Channels (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Countries and Company Analysis, 2024-2032
Buy NowChronic Obstructive Pulmonary Disease (COPD) Market Analysis
Global Chronic Obstructive Pulmonary Disease (COPD) Market was US$ 13.25 Billion in 2023 and will grow US$ 17.22 Billion by 2032, with a CAGR of 2.95% from 2024 to 2032. The rise in COPD instances worldwide is one of the main factors expected to propel the market's expansion and demand in the chronic obstructive pulmonary disease segment. Additionally, it is projected that during the course of the forecast period, rising youth cigarette usage and increased public awareness of the advantages of using generic pharmaceuticals would both support the growth of the worldwide market. Additionally, it is anticipated that growing public awareness and healthcare spending in developing and underdeveloped countries will aid in the market's rise.
Chronic Obstructive Pulmonary Disease (COPD) Market Overview
Chronic obstructive pulmonary disease (COPD) is a widespread, treatable, and avoidable illness marked by persistent respiratory symptoms and restricted airflow because of abnormalities in the airways and/or alveoli, which are typically brought on by prolonged exposure to harmful particles or gases. Complex pathogenic pathways are involved in the etiology of COPD, leading to different subgroups with specific traits and patterns of progression. Variations in the frequency of exacerbations, airflow restriction, and lung function degradation are caused by this diversity. Significant issues in managing COPD arise from ineffectively addressing this diversity.
A common result of misdiagnosing or underdiagnosing COPD is incorrect or inadequate treatment. Very few cases are identified out of all the cases. Underdiagnosis arises from both patients' and doctors' inability to understand the importance of symptoms. In addition, a lot of patients with COPD are misdiagnosed as having lower respiratory tract infections, asthma, or smoker's cough. According to the COPD endotypes, some patients display clinical traits that deviate from the typical symptom profile. The diagnosis of COPD with spirometry has been shown to be efficient and objective, non-invasive, sensitive to early change, and repeatable when compared to other diseases whose diagnosis is challenging. With the availability of portable tools, it can be done practically anywhere, and most healthcare professionals can do it with the appropriate training.
| Report Features | Details |
|
Base Year |
2023 |
|
Forecast Years |
2024 - 2032 |
|
Historical Years |
2019 - 2023 |
|
Market Size in 2023 |
US$ 13.25 Billion |
|
Market Forecast in 2032 |
US$ 17.22 Billion |
|
Market Growth Rate (2024-2032) |
2.95% |
Growth Factors in the Chronic Obstructive Pulmonary Disease (COPD) Industry
Individual Organizations' Awareness Campaigns to Promote Market Growth
According to a 2019 National Center for Biotechnology Information study, there were 212.3 million documented instances of chronic obstructive pulmonary disease (COPD) worldwide. COPD was responsible for 3.3 million deaths and 74.4 million years of life with a handicap. Furthermore, according to the American Lung Association, 3.6% of adults who were 18 years of age or older, or 9.0 million adults, had chronic bronchitis in 2018. 6.6% of adults, or 16.4 million people, were diagnosed with COPD (chronic bronchitis, emphysema, or COPD). Therefore, it is expected that the market would develop in the near future due to the increase in the incidence of chronic obstructive pulmonary disease.
Furthermore, according to information released by the National Heart, Lung, and Blood Institute, the community for people with chronic obstructive pulmonary disease (COPD) gets together in November of each year to advance knowledge of this progressive lung disease, which affects millions of people in the US. Increased public knowledge of chronic obstructive pulmonary disease (COPD) and its symptoms is also crucial because treatment and early detection can both enhance quality of life.
Increased Use of More Potent Combination Therapy to Quicken Market Expansion
LABA-ICS, triple therapy, LAMA-ICS, and other combination medications are examples of combination therapies. Combination therapy is becoming more and more popular because it works better than using corticosteroids and bronchodilators separately. In addition, one of the main factors expected to propel the global chronic obstructive pulmonary disease market in the upcoming years is an increase in the number of patients who were successfully treated with combination therapy but did not show any signs of recovery with bronchodilators or corticosteroid treatments. Additionally, combination therapy is thought to be superior to monotherapy in terms of symptom and quality of life improvement.
North America Chronic Obstructive Pulmonary Disease (COPD) Market Overview
Regionally, North America led the market for chronic obstructive pulmonary disease. The United States and Canada are the main nations driving the market's expansion. In the region of North America, the United States holds the largest proportion. In the US, there are over 16 million people with COPD, and many more do not even know they have the condition. More than half of those with diagnoses are women. The Centers for Disease Control and Prevention (CDC) report that COPD is a leading cause of disability and the sixth most prevalent cause of death in the United States. It is projected that COPD costs in the United States will increase to around $40 billion annually, or a total of $800 billion, during the next 20 years. Screening and case-finding approaches have been employed to identify undiagnosed COPD; case-finding has been recommended by the 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline and the amended United States Preventive Services Task Force (USPTF) recommendation.
As of October 2023, the American Lung Association has maintained its membership in the Breath Better Network and is providing a range of national programs targeted at lung health promotion and lung disease prevention. To increase awareness of the disease's impacts, the American Lung Association has released a variety of state-specific COPD prevalence profiles. The next major objective will be to build on the achievements of the Early Signs of COPD campaign by highlighting the risks and early detection of occupational COPD. In 2024, the group intends to release a COPD National Indicator Report that will offer additional details on the disease's management, diagnosis, treatment, and prevention.
Chronic Obstructive Pulmonary Disease (COPD) Market Company Overview
Some of the industry leaders seen in the Global Chronic Obstructive Pulmonary Disease (COPD) Market Includes AstraZeneca, Pfizer, Inc., GlaxoSmithKline plc., Novartis AG, Astellas Pharma Inc., Abbott Laboratories, Boehringer Ingelheim International GmbH, Almirall.
Chronic Obstructive Pulmonary Disease (COPD) Market News
In April 2024, A report on the results of the Phase 2a COURSE trial for TEZSPIRE (tezepelumab-ekko) in patients with chronic obstructive pulmonary disease was issued by Amgen. Tezelumab was found to statistically lower the annualized rate of moderate-to-severe COPD exacerbations by 17%.
In March 2024, in head-to-head research using a human tissue model of chronic obstructive pulmonary disease, ASLAN Pharmaceuticals Ltd. reported new, encouraging translational evidence that supports eblasakimab's potential as a biologic therapy for COPD. The study pitted eblasakimab against dupilumab.
In February 2024, Regeneron Pharmaceuticals, Inc. and Sanofi declared that the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) in a sixth potential indication as an add-on maintenance treatment in specific adult patients with uncontrolled chronic obstructive pulmonary disease had been accepted for Priority Review by the US FDA.
In September 2024, Verona Pharma plc said that the company's New Drug Application (NDA) for ensifentrine, which seeks clearance for the maintenance treatment of patients with chronic obstructive pulmonary disease, has been authorized by the US Food and Drug Administration (FDA).
Types – Market breakup in 2 viewpoints:
- Chronic Bronchitis
- Emphysema
Treatment Types – Market breakup in 4 viewpoints:
- Drugs
- Oxygen Therapy
- Surgery
- Others
Distribution Channel– Market breakup in 3 viewpoints:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Country – Market breakup in 25 viewpoints:
North America
- United States
- Canada
Europe
- France
- Germany
- Italy
- Spain
- United Kingdom
- Belgium
- the Netherlands
- Turkey
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Thailand
- Malaysia
- Indonesia
- New Zealand
Latin America
- Brazil
- Mexico
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- United Arab Emirates
All the Key players have been covered from 4 Viewpoints:
- Overviews
- Recent Developments & Strategies
- Product Portfolio & Product Launch in Last 1 Year
- Revenue
Company Analysis:
- AstraZeneca
- Pfizer, Inc.
- GlaxoSmithKline plc.
- Novartis AG
- Astellas Pharma Inc.
- Abbott Laboratories
- Boehringer Ingelheim International GmbH
- Almirall
Report Details:
| Report Features | Details |
| Base Year |
2023 |
| Historical Period |
2019 - 2023 |
| Forecast Period |
2024 - 2032 |
| Market |
US$ Billion |
| Segment Covered |
Type, Treatment, Distribution Channels, and Countries |
| Countries Covered |
|
| Companies Covered |
|
| Customization Scope |
20% Free Customization |
| Post-Sale Analyst Support |
1 Year (52 Weeks) |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
Key Questions Answered in This Report:
- How big is the Chronic Obstructive Pulmonary Disease (COPD) industry?
- What is the Chronic Obstructive Pulmonary Disease (COPD) industry growth rate?
- Who are the key players in Chronic Obstructive Pulmonary Disease (COPD) industry?
- What are the factors driving the Chronic Obstructive Pulmonary Disease (COPD) industry?
- Which Region held the largest market share in the Chronic Obstructive Pulmonary Disease (COPD) industry?
- What segments are covered in the Chronic Obstructive Pulmonary Disease (COPD) Market report?
Customization Services available
- Analysis of Market Size and Its Segments
- More Company Profiles (Upto 10 without any additional cost):
- Additional Countries (Other than mentioned Countries):
- Region/Country Specific Reports:
- Market Entry Strategy:
- Region-Specific Market Dynamics:
- Regional Market Share Analysis:
- Trade Analysis:
- Production Insights:
- Others Customized Requests:
For more information contact our analysts.
Need More Assistance?
- Talk to our analysts to get more precious information on the current market trends.
- Include more countries and segments and customize the report based on the final requirement.
- Get a competitive advantage in your industry by knowing the report findings and making a positive impact on your revenues and operations.
- Our analysts are always ready to provide more help and pertinent information if you need any additional assistance.
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Chronic Obstructive Pulmonary Disease (COPD) Market
6. Market Share
6.1 By Type
6.2 By Treatment
6.3 By Distribution Channels
6.4 By Countries
7. By Types
7.1 Chronic Bronchitis
7.2 Emphysema
8. By Treatment Types
8.1 Drugs
8.2 Oxygen Therapy
8.3 Surgery
8.4 Others
9. By Distribution Channels
9.1 Hospital Pharmacies
9.2 Retail Pharmacies
9.3 Online Pharmacies
10. Countries
10.1 North America
10.1.1 United States
10.1.2 Canada
10.2 Europe
10.2.1 France
10.2.2 Germany
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Belgium
10.2.7 Netherlands
10.2.8 Turkey
10.3 Asia Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 Australia
10.3.5 South Korea
10.3.6 Thailand
10.3.7 Malaysia
10.3.8 Indonesia
10.3.9 New Zealand
10.4 Latin America
10.4.1 Brazil
10.4.2 Mexico
10.4.3 Argentina
10.5 Middle East & Africa
10.5.1 South Africa
10.5.2 Saudi Arabia
10.5.3 United Arab Emirates
11. Porter's Five Forces Analysis
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Competition
11.4 Threat of New Entrants
11.5 Threat of Substitutes
12. SWOT Analysis
12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threats
13. Company Analysis
13.1 AstraZeneca
13.1.1 Overviews
13.1.2 Recent Developments & Strategies
13.1.3 Product Portfolio & Product Launch in Last 1 Year
13.1.4 Revenue
13.2 Pfizer, Inc.
13.2.1 Overviews
13.2.2 Recent Developments & Strategies
13.2.3 Product Portfolio & Product Launch in Last 1 Year
13.2.4 Revenue
13.3 GlaxoSmithKline plc.
13.3.1 Overviews
13.3.2 Recent Developments & Strategies
13.3.3 Product Portfolio & Product Launch in Last 1 Year
13.3.4 Revenue
13.4 Novartis AG
13.4.1 Overviews
13.4.2 Recent Developments & Strategies
13.4.3 Product Portfolio & Product Launch in Last 1 Year
13.4.4 Revenue
13.5 Astellas Pharma Inc.
13.5.1 Overviews
13.5.2 Recent Developments & Strategies
13.5.3 Product Portfolio & Product Launch in Last 1 Year
13.5.4 Revenue
13.6 Abbott Laboratories
13.6.1 Overviews
13.6.2 Recent Developments & Strategies
13.6.3 Product Portfolio & Product Launch in Last 1 Year
13.6.4 Revenue
13.7 Boehringer Ingelheim International GmbH
13.7.1 Overviews
13.7.2 Recent Developments & Strategies
13.7.3 Product Portfolio & Product Launch in Last 1 Year
13.7.4 Revenue
13.8 Almirall
13.8.1 Overviews
13.8.2 Recent Developments & Strategies
13.8.3 Product Portfolio & Product Launch in Last 1 Year
13.8.4 Revenue
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com